Female rats and males treated with diethylstilbesterol (DES) were more resistant to i.v. pneum~coccal challenge than were untreated males. These observations may parallel the clinical findings.
INCREASED PESISTANCE TO PNEIMOCOCCAL INFECTION IN FEMALE RATS
AND DIETHYLSTILBESTEGOL TREATED MALES. Robert H. Drachman, Dept. of Ped., Johns Hopkins Univ. School of Med., Baltimore.
Female rats and males treated with diethylstilbesterol (DES) were more resistant to i.v. pneum~coccal challenge than were untreated males. These observations may parallel the clinical findings.
The i.v. LD50 in male rats for Pneunococcus Type 25 (Pn25) is 5x10~ viable organisms. Challenge of female rats with this LDS0 dose of the Pn25 resulted in a significantly lower mrtality. Splenectomized m l e and female rats were challenged i.v. with the same numbers of viable pneunococci. All m l e s died, while about one-half of the females survived. DES was given s.c., 0.5 to 1 mg per day for 5 days to male rats weighing about 200 gm, while similar control rats received cotton seed oil only, the vehicle for the DES. Body weight decreased about 35 gm by day 6. On day 8 DES treated males and controls were challenged i.v. with the LD50 dose of Pn25. Mortality in the DES treated males was comparable to that in females and was significantly different from mortality in cotton seed oil treated control males. In vitro phagocytic studies using the Pn25 as the test particle and two-way combinations of DES treated and normal cells and serum failed to reveal differences in cellular phagocytic activity or levels of s e w opsonizing activity. In vivo DES was capable of producing changes in male rats which caused them to resemble females in their resistance to i.v. pneumococcal challenge. C3a and C5a, products of complement (C) activation, produce histamine release (HR) from guinea pig mast cells and cause mast cell degranulation when injected into human skin. Since complementmediated histamine release from human blood leukocytes has not been demonstrated, the present study was undertaken.
The alternate pathway of C was activated by incubating fresh human serum with zymosan. HR from autologous leukocytes was assayed fluorometrically. In 1 6 normal non-atopic donors 45% -+ 10% (mean -+ SD) of intmcellular histamine was released from leukocytes incubated with zymosan-activated serum. Evidence that C3a and C5a were generated included the following: 1)chemotaxis of PMN's was demonstrated after zymosan treatment of serum, and 2)HR was prevented by heating the serum at 56OC or by absorption with anti-C3 or anti-C5. Basophils from certain allergic subjects will secrete histamine when exposed to appropriate antigens; after repeated washings this reactivity is lost. To examine the possibility that washing removes a membrane-bound factor other than IgE necessary for antigenic histamine release, allogeneic unreactive cells from allergic donors were exposed to washes from reactive cells then challenged with antigen. Histamine release was measured by the usual methods (J.E. M. 120: 507, 1964) . Reactive leukocytes were separated in Dextran, washed twice in Tris BSA buffer (pH 7.4) and the washes saved. Unreactive ce3ls were similarly separated, washed, then incubated in Tris BSA buffers with added ~a * and big* for one hour at 37'C., then resuspended with fresh Tris BSA cafe and ~g * buffer for ragweed antigen challenge. Washes from two or four reactive donors were capable of inducing non-reactive cells to release 62-100% total histamine on antigen challenge; no more than 10% total histamine was released from incubated cells not exposed to antigen. Allogeneic cells from normal non-allergic donors could not be induced to release histamine. The facilitating ability of the washes was not destroyed at 56'C. for one hour and was non-dializable. We concluded that leukocytes capable of antigenic histamine release have a protein on their surface which is not IgE and which is necessary for antigenic histamine release. The correlation between phytohemagglutinin (PHA) induced blast cel l transformation (BCT) and product ion of lymphotoxin (LT), a cytotoxic mediator of cellular imnunity, was studied in the cord blood lymphocytes of 17 normal newborns. Twelve normal adults served as controls. BCT was estimated as uptake of 3-H-thymidine, and LT as the percent inhibition of DNA synthesis of growing target cells. BCT by newborn lymphocytes was slightly greater than that of adults. By contrast, LT production by the newborns was only 40% that of the adults. Calculation of an "LT Index" (ratio of LT product ion to BCT) revealed that for any degree of BCT, newborn lymphocytes produced only one-fourth as much LT as did adult cells. In 6 infants, the percent of lymphocytes forming rosettes with sheep red cel Is (T-cell rosettes) averaged 80% (range 63-90x1, which is comparable to that of adults.
The combination of impaired mediator production with normal BCT represents a dissociation of lymphocyte function which appears to be a stage in the normal maturation of cellular immune competence. This may, in part, explain the undue susceptibility of newborn infants to certain mycobacterial, fungal and viral infections. 925 1 -labelled transplantation alloantibody was injected into long surviving, enhanced and recently transplanted, nonenhanced kidney grafts. Both types of grafts bound the same amount of specific antibody and subsequently released it at a similar rate indicating a dynamic state of antigen turnover by renal allografts and an undiminished number of free antigen sites in Ion surviving enhanced grafts. In vitro studies showed that 925 1 -label led a1 loantibody which combined specifically with target cells exhibited similar phenomenon as grafts in vivo. After 15-18 hours of incubation, 27.5-55.8% of bound label was shed from target cells into surrounding medium and serial elution studies showed that after 183 hours of incubation in vitro > 90% of counts specifically attached were shed. The released labelled material contained little specific reactivity indicating that either released antibody was aggregated or degraded, the radiolabel had been stripped from the antibody molecule or the antibody had been released combined with antigen i.e. complex. Subsequent studies utilizing gel filtration and radioimmunoassay were employed in attempts to characterize released material.
ENHANCED HOST DEFENSE MECHANISM WITH PHENYL-IMIDOTHIOZOLE. Gerald W. Fischer, Vernon T. Oi, Edgar P. Ampaya, James L.
Kelley and James W. Bass. Dept. of Pediatrics, Tripler Army Medical Center, Honolulu, Hawaii.
Phenyl-imidothiazole (PIT), an immunologic stimulant, was studied in newborn Wistar rats to evaluate its effectiveness in modifying infection induced by challenge with bacterial pathogens. PIT (0.03 mg in 0.03 ml of sterile H20) or a placebo (0.03 ml sterile H20) was given (s.c.) on the 2d, 3d, and 4th da s of life. On the 3d day of life Staphylococcus x aureus (10 CFU) or group A beta hemolytic streptococci (~O~CFU) was injected (s.c.) at a different site. Survival in animals pretreated with PIT challenged with Staphylococci was 41/45; it was only 3/59 in those with the placebo (P=<.001). Survival in animals pretreated with PIT and challenged with Streptococci was 11/12; and 2/13 in those that had received the placebo (P=<.005). 20 of 20 PIT controls survived. Delay in PIT administration until challenge on day 3 showed no protection (2118). PIT was not effective in vitro. Nonpretreated animals died with cellulitis of the --skin and subcutaneous tissue extending rapidly from the injection site. Pretreated animals thrived while developing a localized subcutaneous abscess which healed leaving a small scar at the injection site. Pretreatment with PIT obviously potentiates the primary inflammatory response providing protection against bacterial challenge in this newborn animal model. It may have some clinical application in management of patients at high risk to bacterial pathogens of this nature.
